THE QUESTION REGISTER
BPC-157 TB-500 FAQ: The Wolverine Blend, Answered
Twenty-five questions on the BPC-157 TB-500 blend, each answered directly and cited where the answer makes a quantitative claim.
Mechanism and definition
The BPC-157 TB-500 blend raises the same questions again and again: what each peptide is, how each works, and whether they truly act together. The answers below are grouped by theme and drawn from the published record.
Evidence and efficacy
These questions ask what the studies actually establish — and, repeatedly, the answer is that the evidence is single-compound and preclinical, never a combination trial.
Dosage, pharmacokinetics, and handling
Dosing questions about the blend run into the same wall: there is no validated human dose, frequency, or cycle for the combination. The answers describe what was studied in animals and how research material is handled, never a protocol.
Safety
Safety questions about the blend inherit the uncertainty of two unapproved peptides with thin human data — and one specific preclinical signal worth naming directly.
Legal and regulatory
The regulatory answers are drawn from the audited FDA record. They state present-tense facts and reference the July 2026 PCAC meeting only as a scheduled discussion of substances under evaluation.